Monoclonal Anti-Influenza Virus H1 Hemagglutinin (HA), A/South Carolina/1/1918 (H1N1), Clone 39E4 (produced *in vitro*)

Catalog No. NR-13453

For research use only. Not for human use.

Contributor:
Adolfo Garcia-Sastre, Ph.D., Departments of Medicine and Microbiology, and Global Health and Emerging Pathogens Institute, Mount Sinai School of Medicine, New York, New York

Manufacturer:
BEI Resources

Product Description:
Antibody Class: IgG2aκ
Mouse monoclonal antibody prepared against the H1 hemagglutinin (HA) of influenza virus A/South Carolina/1/1918 (H1N1) was purified from clone 39E4 hybridoma supernatant by protein G affinity chromatography. The B cell hybridoma was generated by the fusion of Sp2/0 BALB/c mouse myeloma cells with splenocytes from mice immunized by DNA vaccination with a plasmid encoding the HA of influenza virus, A/South Carolina/1/1918 (H1N1) and then boosted with whole inactivated virus.

Material Provided:
Each vial of NR-13453 contains approximately 100 µL of purified monoclonal antibody in PBS. The concentration, expressed as mg per mL, is shown on the Certificate of Analysis.

Packaging/Storage:
NR-13453 was packaged aseptically in screw-capped plastic cryovials and is provided frozen on dry ice. NR-13453 should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be avoided.

Functional Activity:
NR-13453 is reactive against the H1 HA of influenza virus, A/South Carolina/1/1918 (H1N1) in ELISA, hemagglutination inhibition assays, and western blot assays.[1]

Citation:
Acknowledgment for publications should read "The following reagent was obtained through BEI, NIAID, NIH: Monoclonal Anti-Influenza Virus H1 Hemagglutinin (HA), A/South Carolina/1/1918 (H1N1), Clone 39E4 (produced *in vitro*), NR-13453."

Biosafety Level: 1
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:
You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:
This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:
1. A. Garcia-Sastre, personal communication.
2. Manicassamy, B., et al. "Protection of Mice against Lethal Challenge with 2009 H1N1 Influenza A Virus by 1918-Like and Classical Swine H1N1 Based Vaccines." PLoS Pathog. 6 (2010): e1000745. PubMed: 20126449.
3. Glaser, L., et al. "A Single Amino Acid Substitution in 1918 Influenza Virus Hemagglutinin Changes Receptor

Binding Specificity." J. Virol. 79 (2005): 11533-11536. PubMed: 16103207.

4. Tumpey, T. M., et al., "Existing Antivirals are Effective against Influenza Viruses with Genes from the 1918 Pandemic Virus." Proc. Natl. Acad. Sci. U. S. A. 99 (2002): 13849-13854. PubMed: 12368467.

Support Provided by NIAID

BEI Resources
www.beiresources.org

E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898